on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
Financial position of GenSight Biologics as of September 30, 2026
GenSight Biologics reported cash and cash equivalents of €0.7 million as of September 30, 2026, down from €1.7 million as of June 30. The exemption access programs generated €1.7 million in revenue in the third quarter, contributing to a total of €8.2 million since their inception. This decrease in cash is due to the summer pause in treatments and investments in manufacturing technology transfer and preparation for the RECOVER study.
Despite these inflows, the company anticipates a funding requirement of approximately €16 million, primarily for the Phase III RECOVER trial. Bridge financing or additional treatments are being considered to extend resources until March 2027.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news